An uncommon take on drug development trends
from the experts at Worldwide Clinical Trials
Marie is the co-founder and managing director of phaware, a global association dedicated to raising awareness of pulmonary hypertension (PH), which her daughter, Chloe, was diagnosed with at the age of eight months. Not only that, but Chloe was “patient number one” in the first clinical trial for the first PH drug, a drug that just in the last year has been approved for children. Marie speaks passionately about her experience, how she felt and what she did after receiving the news that finally, the drug that prolonged her daughter’s life would now be given to other children, and she shares her personal thoughts on the value of a clinical trial.
ABOUT WORLDWIDE CLINICAL TRIALS
Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60+ countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.